Skip to main content
. 2015 Oct 16;6(35):37948–37964. doi: 10.18632/oncotarget.5698

Figure 3. Immunocytochemistry of SRC and Met localization.

Figure 3

Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.